GSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints. The primary endpoints of the SWIFT-1 and ...

Exdensur (depemokimab) in two indications, including: As an add-on maintenance treatment for severe asthma with type 2 ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant ...

GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab ...

European Commission approves GSK’s Exdensur for severe asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, February 18, 2026, 09:00 Hrs [IST] GSK plc announced the ...

The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.

(Alliance News) - GSK PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of depemokimab in two indications. The ...

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing ...